Global research to find creative and disruptive technologies
SEARCH NOTE: Use the " " to get an exact search. Use % wildcard for partial. For example "cardio" would deliver only cardio whereas %cardio% would deliver every record that had cardio anywhere in the name.
Global Database of Emerging Companies
The OneMedPlace Global Investment Platform aims to assist in bridging the funding gap for emerging growth companies. Qualified investors will soon be invited to log-in to participate in this network and contact companies directly.
An investor subscription to the platform will include access to business intelligence by research area – research reports, interviews, and posts curated by expert contributors – and deal-flow, with detailed multimedia-driven tear sheets and analyst summaries of companies in the space.
If you are an investor, you can pre-register by filling out this investor survey. Pre-registration to the Global Investment Platform will include a complimentary ticket to OneMedForumNY 2013, June26-27th at the Metropolitan Club in midtown NYC. Pre-registration also includes access to our deal-flow reports and subscription to our sector research reports.
*Your information will not be published or provided to any third party.
If you are a company executive and would like to learn more about our assets and reaching investors, contact Matt Margolis, Managing Editor, OneMedPlace at email@example.com or give us a call at 212.734.1008.
The Woodlands, TX, USA | Develops treatments for autoimmune diseases.
keywords: Regenerative medicine, immunotherapy, multiple sclerosis, secondary progressive multiple sclerosis, inflammatory disease, MS The Woodlands TX USA Neil Warma, President and Chief Executive Officer; Jaye Thompson, Ph.D., Senior-Vice President of Clinical Development and Regulatory Affairs; Don Healy Ph.D., Vice-President of Scientific Development and Manufacturing; Donna R. Rill, Senior Vice-President of Operations; John Ginzler
Charlottesville, United States | Repurposing drugs for unmet clinical needs.
keywords: ocular, opthalmology, diabetes, obesity, CNS, oncology Charlottesville VA United States Andreas Persidis Ph.D., CEO, Co-Founder; Aris Persidis Ph.D, President, Co-Founder; Graham Anthony, MBA
Fort Worth, TX, USA | Provides collagen based wound care technology.
keywords: Wound care, regenerative medicine, woundcare Fort Worth TX USA Robert Lutz, CEO; Cathy Bradshaw, President of Wound Care Innovations, LLC Division; Barry E. Constantine, Project Consultant, Quality Manager
Chengdu, China | Short Version:James Jiayuan Tong MD, PhD. is CFO, CBDO and Board Director of Tianyin Pharmaceuticals (NYSE Amex: TPI), headquartered at Chengdu, China. Prior to joining Tianyin in 2010, Dr. Tong was the Head of China Healthcare Investment Banking at ROTH Capital and before that a biotechnology analyst at Rodman & Renshaw. Prior to his Wall Street career, he was Principal Investigator at Marine Biological Laboratory at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine. Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program where he developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Dr. Tong received his medical degree from Peking University Health Science Center.
Long version. Dr. James Jiayuan Tong Dr. Tong joined Tianyin as Chief Financial Officer and Chief Business & Development Officer, and a member of the Company's Board of Directors on April 1, 2010. Prior to his position at Tianyin, Dr. Tong was the Head of China Healthcare Investment Banking at ROTH Capital Partners, Newport Beach, CA. He initially joined ROTH as an equity research analyst, spearheading ROTH's effort in China healthcare universe, covering a series of U.S.-listed Chinese pharmaceutical, biotech, medical devices and drug retail businesses. Prior to that, Dr. Tong was a biotechnology analyst at Rodman & Renshaw, New York, covering biotech entities focusing on molecular diagnostics and cures for Alzheimer's disease, multiple sclerosis and cancer. Before his Wall Street career, Dr. Tong was Principal Investigator at Marine Biological Laboratory (MBL) sponsored by Grass Foundation at Woods Hole, MA and a Senior Research Fellow at University of California, Irvine (UCI). Dr. Tong was awarded Ph.D. in Neurobiology and Behavior from Cold Spring Harbor Laboratory / Stony Brook University Neuroscience program. He developed an innovative method to significantly extend life spans of animals based on his work on mitochondria, aging and learning disorders in Neurofibromatosis-1 (NF1) disease. He published three first-authored Nature articles and currently holds two patents. Dr. Tong received his medical degree from Peking University Health Science Center.